BioCentury
ARTICLE | Financial News

Gemini raises $42.5M series A

October 20, 2017 7:22 PM UTC

On Oct. 17, Gemini Therapeutics Inc. (Cambridge, Mass.) raised $42.5 million in a series A round co-led by Atlas Venture, Lightstone Ventures and OrbiMed Advisors. The company is developing therapies for complement-mediated diseases, with an initial focus on subpopulations of dry age-related macular degeneration (AMD) where the disease is driven by a mutation in the complement pathway.

While details of the company's pipeline have not yet been disclosed, Atlas' Jason Rhodes told BioCentury that Gemini will develop several modalities, including mAbs, recombinant proteins and gene therapies. He said the company would also develop therapies for rare diseases where a loss of function mutation in the complement pathway may be involved, such as atypical hemolytic uremic syndrome (aHUS)...